These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 6099364

  • 1. Protamine inhibits platelet derived growth factor receptor activity but not epidermal growth factor activity.
    Huang JS, Nishimura J, Huang SS, Deuel TF.
    J Cell Biochem; 1984; 26(4):205-20. PubMed ID: 6099364
    [Abstract] [Full Text] [Related]

  • 2. Cell cycle variation in 125I-labeled epidermal growth factor binding in chemically transformed cells.
    Robinson RA, Branum EL, Volkenant ME, Moses HL.
    Cancer Res; 1982 Jul; 42(7):2633-8. PubMed ID: 6979383
    [Abstract] [Full Text] [Related]

  • 3. Suramin binds to platelet-derived growth factor and inhibits its biological activity.
    Hosang M.
    J Cell Biochem; 1985 Jul; 29(3):265-73. PubMed ID: 4077932
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716.
    Major TC, Keiser JA.
    J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.
    Lipson KE, Pang L, Huber LJ, Chen H, Tsai JM, Hirth P, Gazit A, Levitzki A, McMahon G.
    J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635
    [Abstract] [Full Text] [Related]

  • 6. Differential inhibitory effects of TGF-beta on EGF-, PDGF-, and HBGF-1-stimulated MG63 human osteosarcoma cell growth: possible involvement of growth factor interactions at the receptor and postreceptor levels.
    Mioh H, Chen JK.
    J Cell Physiol; 1989 Jun; 139(3):509-16. PubMed ID: 2472412
    [Abstract] [Full Text] [Related]

  • 7. Heterologous regulation of EGF receptors in fibroblastic cells.
    Olashaw NE, Pledger WJ.
    J Cell Biochem; 1987 Jun; 34(2):143-9. PubMed ID: 3496345
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
    Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, Ullrich A, Berens ME, Hersh E, McMahon G, Hirth KP, Powell TJ.
    Clin Cancer Res; 1997 Jul; 3(7):1167-77. PubMed ID: 9815796
    [Abstract] [Full Text] [Related]

  • 9. Identification of a PDGF-like mitoattractant produced by NIH/3T3 cells after transformation with SV40.
    Bleiberg I, Harvey AK, Smale G, Grotendorst GR.
    J Cell Physiol; 1985 May; 123(2):161-6. PubMed ID: 2984217
    [Abstract] [Full Text] [Related]

  • 10. Modulation of the epidermal growth factor receptor by brain-derived growth factor in Swiss mouse 3T3 cells.
    Huang SS, Lokeshwar VB, Huang JS.
    J Cell Biochem; 1988 Mar; 36(3):209-21. PubMed ID: 3379102
    [Abstract] [Full Text] [Related]

  • 11. Tumor promoter enhances mitogenesis by PDGF with little effect on PDGF binding.
    Eide BL, Krebs EG, Ross R, Pike LJ, Bowen-Pope DF.
    J Cell Physiol; 1986 Feb; 126(2):254-8. PubMed ID: 3003126
    [Abstract] [Full Text] [Related]

  • 12. Human uterine leiomyoma cells: binding and growth responses to epidermal growth factor, platelet-derived growth factor, and insulin.
    Fayed YM, Tsibris JC, Langenberg PW, Robertson AL.
    Lab Invest; 1989 Jan; 60(1):30-7. PubMed ID: 2536127
    [Abstract] [Full Text] [Related]

  • 13. Modulation of platelet-derived growth factor receptor function in BP3T3, a chemically transformed BALB/c-3T3 cell line.
    Grundy P, Bishayee S, Disa S, Scher CD.
    Cancer Res; 1989 Jul 01; 49(13):3581-6. PubMed ID: 2543499
    [Abstract] [Full Text] [Related]

  • 14. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation.
    Kovalenko M, Gazit A, Böhmer A, Rorsman C, Rönnstrand L, Heldin CH, Waltenberger J, Böhmer FD, Levitzki A.
    Cancer Res; 1994 Dec 01; 54(23):6106-14. PubMed ID: 7954456
    [Abstract] [Full Text] [Related]

  • 15. Use of selective tyrosine kinase blockers to monitor growth factor receptor dephosphorylation in intact cells.
    Böhmer FD, Böhmer A, Obermeier A, Ullrich A.
    Anal Biochem; 1995 Jul 01; 228(2):267-73. PubMed ID: 8572305
    [Abstract] [Full Text] [Related]

  • 16. Epidermal growth factor receptor, platelet-derived growth factor receptor, and c-erbB-2 receptor activation all promote growth but have distinctive effects upon mouse mammary epithelial cell differentiation.
    Taverna D, Groner B, Hynes NE.
    Cell Growth Differ; 1991 Mar 01; 2(3):145-54. PubMed ID: 1676295
    [Abstract] [Full Text] [Related]

  • 17. Differential responsiveness of normal and simian virus 40-transformed BALB/c 3T3 cells to retinoic acid: rapid enhancement of epidermal growth factor receptor binding in a simian virus 40-3T3 variant.
    Chen JK, Li LW, Mioh H.
    Cancer Res; 1987 Oct 01; 47(19):4995-9. PubMed ID: 3040236
    [Abstract] [Full Text] [Related]

  • 18. Mechanisms of inhibition by heparin of PDGF stimulated MAP kinase activation in vascular smooth muscle cells.
    Pukac LA, Carter JE, Ottlinger ME, Karnovsky MJ.
    J Cell Physiol; 1997 Jul 01; 172(1):69-78. PubMed ID: 9207927
    [Abstract] [Full Text] [Related]

  • 19. Benzo(a)pyrene inhibits epidermal growth factor binding and receptor autophosphorylation in human placental cell cultures.
    Guyda HJ, Mathieu L, Lai W, Manchester D, Wang SL, Ogilvie S, Shiverick KT.
    Mol Pharmacol; 1990 Feb 01; 37(2):137-43. PubMed ID: 2154666
    [Abstract] [Full Text] [Related]

  • 20. Modulation of the epidermal growth factor receptor by mitogenic ligands: effects of bombesin and role of protein kinase C.
    Zachary I, Rozengurt E.
    Cancer Surv; 1985 Feb 01; 4(4):729-65. PubMed ID: 3916643
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.